<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?origin publisher?><?properties no_embargo?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetologia</journal-id><journal-title>Diabetologia</journal-title><issn pub-type="ppub">0012-186X</issn><issn pub-type="epub">1432-0428</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18292987</article-id><article-id pub-id-type="publisher-id">932</article-id><article-id pub-id-type="doi">10.1007/s00125-008-0932-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Joint effects of HLA, <italic>INS</italic>, <italic>PTPN22</italic> and <italic>CTLA4</italic> genes on the risk of type 1 diabetes</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Bj&#x000f8;rnvold</surname><given-names>M.</given-names></name><address><email>marit.bjornvold@medisin.uio.no</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Undlien</surname><given-names>D. E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Joner</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dahl-J&#x000f8;rgensen</surname><given-names>K.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nj&#x000f8;lstad</surname><given-names>P. R.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Akselsen</surname><given-names>H. E.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gervin</surname><given-names>K.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>R&#x000f8;nningen</surname><given-names>K. S.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stene</surname><given-names>L. C.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label>Institute of Medical Genetics, Faculty Division Ullev&#x000e5;l University Hospital, University of Oslo, P.O. Box 1036, Blindern, NO-0315 Oslo, Norway </aff><aff id="Aff2"><label>2</label>Department of Medical Genetics, Ullev&#x000e5;l University Hospital, Oslo, Norway </aff><aff id="Aff3"><label>3</label>Department of Paediatrics, Ullev&#x000e5;l University Hospital, Oslo, Norway </aff><aff id="Aff4"><label>4</label>Faculty of Medicine, University of Oslo, Oslo, Norway </aff><aff id="Aff5"><label>5</label>Section for Paediatrics, Department of Clinical Medicine, University of Bergen, Bergen, Norway </aff><aff id="Aff6"><label>6</label>Department of Paediatrics, Haukeland University Hospital, Bergen, Norway </aff><aff id="Aff7"><label>7</label>Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>2</month><year>2008</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2008</year></pub-date><volume>51</volume><issue>4</issue><fpage>589</fpage><lpage>596</lpage><history><date date-type="received"><day>28</day><month>6</month><year>2007</year></date><date date-type="accepted"><day>3</day><month>1</month><year>2008</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag 2008</copyright-statement></permissions><abstract><sec><title>Background/hypothesis</title><p>HLA, <italic>INS</italic>, <italic>PTPN22</italic> and <italic>CTLA4</italic> are considered to be confirmed type 1 diabetes susceptibility genes. HLA, <italic>PTPN22</italic> and <italic>CTLA4</italic> are known to be involved in immune regulation. Few studies have systematically investigated the joint effect of multiple genetic variants. We evaluated joint effects of the four established genes on the risk of childhood-onset type 1 diabetes.</p></sec><sec><title>Methods</title><p>We genotyped 421 nuclear families, 1,331 patients and 1,625 controls for polymorphisms of <italic>HLA-DRB1</italic>, &#x02212;<italic>DQA1</italic> and &#x02212;<italic>DQB1</italic>, the insulin gene (<italic>INS</italic>, <italic>&#x02212;23&#x000a0;HphI</italic>), <italic>CTLA4</italic> (<italic>JO27_1</italic>) and <italic>PTPN22</italic> (<italic>Arg620Trp</italic>).</p></sec><sec><title>Results</title><p>The joint effect of HLA and <italic>PTPN22</italic> on type 1 diabetes risk was significantly less than multiplicative in the case-control data, but a multiplicative model could not be rejected in the trio data. All other two-way gene&#x02013;gene interactions fitted multiplicative models. The high-risk HLA genotype conferred a very high risk of type 1 diabetes (OR 20.6, using the neutral-risk HLA genotype as reference). When including also intermediate-risk HLA genotypes together with risk genotypes at the three non-HLA loci, the joint odds ratio was 61 (using non-risk genotypes at all loci as reference).</p></sec><sec><title>Conclusion</title><p>Most established susceptibility genes seem to act approximately multiplicatively with other loci on the risk of disease except for the joint effect of HLA and <italic>PTPN22</italic>. The joint effect of multiple susceptibility loci conferred a very high risk of type 1 diabetes, but applies to a very small proportion of the general population. Using multiple susceptibility genotypes compared with HLA genotype alone seemed to influence the prediction of disease only marginally.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00125-008-0932-0) contains supplementary material, which is available to authorised users.</p></sec></abstract><kwd-group><title>Keywords</title><kwd><italic>CTLA4</italic></kwd><kwd>Genes</kwd><kwd>HLA</kwd><kwd><italic>INS</italic></kwd><kwd>Interaction</kwd><kwd><italic>PTPN22</italic></kwd><kwd>Type 1 diabetes</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2008</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec5" sec-type="introduction"><title>Introduction</title><p>The risk of complex diseases such as type 1 diabetes is generally thought to be influenced by multiple genetic and non-genetic factors, and it has been hypothesised that interactions between genes, or epistasis, are very common for such diseases [<xref ref-type="bibr" rid="CR1">1</xref>]. The presence of interactions could be one of the reasons why searching for susceptibility loci for many diseases has been less successful than expected [<xref ref-type="bibr" rid="CR2">2</xref>]. When moving from monogenic diseases to complex diseases, it seems reasonable to assess more than one locus at a time, although models become increasingly complex as the number of loci increases [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>Whereas few or no common genetic variants have been firmly established for most common diseases [<xref ref-type="bibr" rid="CR4">4</xref>], there are now at least four genetic loci that are established as causally involved in the aetiology of type 1 diabetes. They give us a unique possibility to evaluate gene&#x02013;gene interactions among established susceptibility genes. Specific allelic combinations of <italic>DRB1</italic>, <italic>DQA1</italic> and <italic>DQB1</italic> in the human leucocyte antigen (HLA) complex, variants in the insulin gene (<italic>INS</italic>), the cytotoxic T lymphocyte antigen-4 gene (<italic>CTLA4</italic>) and the protein tyrosine phosphatase, non-receptor type 22 gene (<italic>PTPN22</italic>) have been repeatedly associated with type 1 diabetes susceptibility [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>] using different approaches. All established loci are thought to be involved somehow in immune regulation, but details of the mechanisms relating the polymorphisms to risk of type 1 diabetes are in most cases poorly understood.</p><p>Evaluating the joint effects of genes contributes important information for risk prediction, and is also thought to provide information about biological interactions, although the latter is controversial and more complex than commonly thought [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p>Previous studies have assessed interaction between HLA and <italic>INS</italic> and reported divergent results [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. The reported results of the joint effect of HLA and <italic>INS</italic> are confusing not only because they have shown diverging results but also because the definitions and terminology of interactions are not consistent [<xref ref-type="bibr" rid="CR19">19</xref>]. The interpretation of statistical interaction depends on the choice of scale used to measure the effects [<xref ref-type="bibr" rid="CR2">2</xref>]. Although additivity of risks is often taken as independence [<xref ref-type="bibr" rid="CR20">20</xref>], multiplicativity of risk is sometimes also taken as independence [<xref ref-type="bibr" rid="CR21">21</xref>]. The joint action of HLA and <italic>INS</italic> has variously been described as being multiplicative [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], additive [<xref ref-type="bibr" rid="CR13">13</xref>], providing evidence of interaction [<xref ref-type="bibr" rid="CR15">15</xref>], and non-interacting [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Few studies have investigated the more recently established susceptibility loci <italic>PTPN22</italic> and <italic>CTLA4</italic> in the context of joint effects on the risk of type 1 diabetes. The studies that have been done have mainly concluded that there is a non-interaction [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>] effect, but here also the results have diverged [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>].</p><p>The aim of our study was to assess the joint effects of the four established susceptibility loci HLA, <italic>INS</italic>, <italic>CTLA4</italic> and <italic>PTPN22</italic> in type 1 diabetes, using a consistent approach with both population-based case-control and family trio designs and with large sample sizes.</p></sec><sec id="Sec6" sec-type="methods"><title>Methods</title><p><bold>Participants</bold> We analysed two independent type 1 diabetes data sets. One nuclear family set consisted of 421 trios with mother, father and one child diagnosed in Norway with type 1 diabetes before age 15&#x000a0;years (225 [53.4%] of the affected children were boys). The families were collected between 1993 and 1997. In families with more than one affected sibling, only the proband was included in the analyses. The case-control data set consisted of 1,331 type 1 diabetes patients (51.9% boys and 48.1% girls) and 1,625 (51.4% boys and 48.6% girls) control participants aged &#x0003c;15&#x000a0;years. In analyses involving age of disease onset, we divided the data sets according to age of disease onset of the affected child into three groups (0&#x02013;4.9, 5&#x02013;9.9 and &#x02265;10&#x000a0;years). The controls were randomly selected from the official population registry among children born between 1985 and 1999 and recruited in 2001, as previously described [<xref ref-type="bibr" rid="CR28">28</xref>]. The patients in the case-control material were from the Norwegian Childhood Diabetes Registry consecutively recruited between 1997 and 2000 [<xref ref-type="bibr" rid="CR29">29</xref>] and between 2002 and 2005. The type 1 diabetes patients and their family members were recruited by the Norwegian Childhood Diabetes Study Group, including all paediatric departments in Norway. All type 1 diabetes patients were diagnosed according to EURODIAB criteria [<xref ref-type="bibr" rid="CR30">30</xref>]. The study was approved by the local ethics committee, and informed consent was obtained from all participants or their parents.</p><p><bold>Genomic DNA extraction and genotyping</bold> In the majority of the type 1 diabetes case-control samples we used DNA extracted from buccal cells [<xref ref-type="bibr" rid="CR31">31</xref>]. In all remaining samples, DNA was extracted from peripheral whole blood using a salting-out protocol. Genotyping of <italic>HLA-DRB1</italic>, <italic>&#x02212;DQA1</italic> and &#x02212;<italic>DQB1</italic> was performed using PCR-SSOP (sequence-specific oligonucleotide probing) mainly following published methods [<xref ref-type="bibr" rid="CR32">32</xref>], or PCR-SSP (sequence-specific primer) [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], or using time-resolved fluorescence technology in the Delfia assay (Perkin-Elmer Life Sciences, Turku, Finland). HLA genotypes were grouped into four risk categories based on <italic>DQB1</italic>, <italic>DQA1</italic> and <italic>DRB1</italic> genotypes, including <italic>DRB1*04</italic> subtyping. The majority of <italic>DRB1*04-DQA1*0301-DQB1*0302</italic> haplotypes in Norway are <italic>DRB1*0401</italic> or &#x02212;<italic>0404</italic> (constituting &#x0003e;94% of the haplotypes) [<xref ref-type="bibr" rid="CR35">35</xref>]. In the present study the other rare subtypes are referred to as <italic>DRB1*04XX</italic>. Because of the almost complete linkage disequilibrium between <italic>INS-VNTR</italic> allele classes and the <italic>&#x02212;23&#x000a0;HphI</italic> polymorphism, we genotyped &#x02212;23&#x000a0;<italic>HphI</italic> (rs689) as a marker for the <italic>INS-VNTR.</italic> The &#x02212;<italic>23&#x000a0;HphI</italic> A allele corresponds to the <italic>VNTR</italic> class I and the <italic>&#x02212;23&#x000a0;HphI</italic> T allele correspond to the <italic>VNTR</italic> class III. In <italic>PTPN22</italic> we genotyped the single nucleotide polymorphism (SNP) <italic>Arg620Trp</italic> (rs2476601). The SNP <italic>JO27_1</italic> (rs11571297) was genotyped in <italic>CTLA4</italic>. SNP genotyping was performed by TaqMan allelic discrimination assays on an ABI 7900HT DNA Analyzer (Applied Biosystems, Foster City, CA USA). Primer and probe sequences are shown in Electronic Supplementary Material (ESM) Table&#x000a0;<xref ref-type="" rid="MOESM1">1</xref>. The PCR conditions are available on request.</p><p><bold>Data analysis</bold> The HLA haplotypes were grouped as high risk, intermediate risk, neutral risk and low risk according to the following criteria: high-risk category, <italic>DRB1*0401/04XX</italic>-<italic>DQA1*03-DQB1*0302/DRB1*03-DQA1*05-DQB1*0201</italic> (<italic>DR4</italic>-<italic>DQ8/DR3-DQ2</italic>); low-risk category, all genotypes with at least one <italic>DQB1</italic>*0602 allele; intermediate-risk category, <italic>DRB1*0404-DQ8/DR3-DQ2</italic>, <italic>DR3-DQ2/DR3-DQ2</italic>, <italic>DR4-DQ8/DR4-DQ8</italic> (with the exception of <italic>DRB1 0404-DQ8</italic> homozygotes, which were grouped as neutral), <italic>DRB1*0401</italic> or <italic>040XX-DQ8/X</italic> (X&#x02260;<italic>DQB1</italic>*<italic>0602</italic> or <italic>DR3-DQ2</italic>). The remaining haplotypes were grouped in the neutral-risk category. For assessment of two-locus joint effects, we pooled genotypes of <italic>INS</italic>, <italic>PTPN22</italic> and <italic>CTLA4</italic> as follows: <italic>INS</italic> class I/I genotypes were compared with I/III together with III/III genotypes. The <italic>PTPN22</italic> TT and CT genotypes were compared with CC. <italic>CTLA4</italic> (<italic>JO27_1</italic>) TT genotypes were compared with TC and CC genotypes. Not all individuals were genotyped for non-HLA polymorphisms because of lack of DNA. We did not exclude individuals with some missing genotypes to prevent the loss of important information when looking at joint effects between polymorphisms. The available numbers of individuals for each analysis are seen in the tables. Data were presented using stratified 2&#x02009;&#x000d7;&#x02009;2 tables and analysed using logistic regression models including interaction (product) terms, in SPSS for Windows (version 14.0; SPSS, Chicago, IL, USA). In addition to formal analyses treating HLA categories as categorical in the logistic regression, we also tested for interactions when treating HLA category as a continuous variable coded 1, 2, 3, 4, thus maximising the power under alternative models where the effect of a non-HLA locus (as measured by the odds ratio [OR]) was assumed to decrease (or increase) (logit) linearly over the four HLA risk categories (test for interaction with one degree of freedom). Case-only analyses were used to estimate interaction parameters and to test for deviation from multiplicative effects using logistic regression [<xref ref-type="bibr" rid="CR36">36</xref>]. In addition to the increased power obtained by utilising all cases (from case-control and trio materials) simultaneously, case-only analyses have increased power by making the implicit assumption that there is no association between the two loci in the population; i.e. the OR for their association is 1.0 in the population. Thus, under reasonable assumptions the case-only analysis makes the most efficient use of data to assess deviation from multiplicative models. In the case-control analysis, likelihood ratio tests comparing nested logistic regression models were used as global tests for interaction. The transmission disequilibrium test [<xref ref-type="bibr" rid="CR37">37</xref>] was performed using the UNPHASED application implemented in the UNPHASED software version 2.4 [<xref ref-type="bibr" rid="CR38">38</xref>]. For the trio data, 95% confidence intervals for the relative risk were estimated using conditional logistic regression in UNPHASED. Receiver operating curve (ROC) and confidence bounds for the area under the curve were estimated assuming a non-parametric distribution and analyses were done using SPSS version 14.0. Genotypes were added sequentially in order of likelihood ratio (or equivalently by the absolute risk conferred by a given genotype combination estimated using Bayes&#x02019; formula). Two four-locus genotype combinations were absent among cases in our material, and a very low value for the estimated absolute risk was imputed for these to allow inclusion in the ROC curve estimation with all four loci simultaneously. A <italic>p</italic> value &#x0003c;0.05 was considered to be statistically significant.</p></sec><sec id="Sec7" sec-type="results"><title>Results</title><p>The single-locus main effects are shown in ESM Table&#x000a0;<xref ref-type="" rid="MOESM2">2</xref> (case-control data) and ESM Table&#x000a0;<xref ref-type="" rid="MOESM3">3</xref> (trios). Compared with the neutral HLA risk category, the high-risk category showed a strong association with type 1 diabetes, with OR 20.6; for the intermediate-risk category the OR was 5.7 and for the low-risk category it was 0.09. <italic>INS</italic>, <italic>PTPN22</italic> and <italic>CTLA4</italic> also showed an association with type 1 diabetes, as expected. The transmission of the risk allele in the nuclear families confirmed the associations in <italic>INS</italic>, <italic>PTPN22</italic> and <italic>CTLA4</italic> (<italic>JO27_1</italic>), although with borderline significance for <italic>JO27_1</italic> (ESM Table&#x000a0;<xref ref-type="" rid="MOESM3">3</xref>).</p><p><bold>Joint effect of HLA and PTPN22</bold> ORs for the effect of <italic>PTPN22</italic> varied across the HLA risk categories and were significant in some of the subgroups. The ORs were smaller for the risk-conferring HLA genotypes, indicating negative deviation from a multiplicative model. A global test of interaction (with 3&#x000a0;<italic>df</italic>) between HLA and <italic>PTPN22</italic> in the logistic regression model confirmed a significant interaction (<italic>p&#x02009;</italic>=&#x02009;0.024). In the trio data, the relative risk conferred by the <italic>PTPN22</italic> T allele was similar in the strata defined by HLA group, with no evidence for deviation from a multiplicative model (ESM Table&#x000a0;<xref ref-type="" rid="MOESM4">4</xref>). A case-only analysis among all cases from the case-control and family materials (ESM Table&#x000a0;<xref ref-type="" rid="MOESM5">5</xref>) supported a significant negative deviation from multiplicative effects, with weaker ORs conferred by <italic>PTPN22</italic> in the HLA risk categories (3&#x000a0;<italic>df</italic> test for interaction; <italic>p&#x02009;</italic>=&#x02009;0.028). When treating HLA-encoded risk as a continuous variable in the analysis (1&#x000a0;<italic>df</italic>), the interaction was even more statistically significant (<italic>p&#x02009;</italic>=&#x02009;0.003). There was no association between HLA and <italic>PTPN22</italic> among the controls (3&#x000a0;<italic>df</italic> test; <italic>p&#x02009;</italic>=&#x02009;0.19). We tried to fit the case-control data to an additive odds model using generalised linear models in STATA (version 9), as described by Skrondal [<xref ref-type="bibr" rid="CR39">39</xref>]. However, convergence was not obtained, suggesting that the data did not fit well to an additive model.</p><p><bold>Joint effect of HLA and INS</bold> The 3&#x000a0;<italic>df</italic> test for interaction between <italic>INS</italic> and HLA was not statistically significant (<italic>p&#x02009;</italic>=&#x02009;0.67). There was also no statistically significant deviation from a multiplicative model in the trio data (test for interaction, <italic>p&#x02009;</italic>=&#x02009;0.5) (ESM Table&#x000a0;<xref ref-type="" rid="MOESM4">4</xref>) or in the case-only analysis (3&#x000a0;<italic>df</italic> test; <italic>p&#x02009;</italic>=&#x02009;0.49) (ESM Table&#x000a0;<xref ref-type="" rid="MOESM5">5</xref>); even when treating HLA-encoded risk as a continuous variable in the analysis there was no significance (1&#x000a0;<italic>df</italic> test, <italic>p&#x02009;</italic>=&#x02009;0.12). There was also no association between <italic>INS</italic> and HLA among controls, as expected (3&#x000a0;<italic>df</italic> test; <italic>p&#x02009;</italic>=&#x02009;0.41).</p><p><bold>Joint effect of HLA and CTLA4</bold> The ORs for <italic>CTLA4</italic> in the different HLA categories (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) indicated no deviation from a two-locus multiplicative model (3&#x000a0;<italic>df</italic> test; <italic>p&#x02009;</italic>=&#x02009;0.53). This was also the case in the trio data set (ESM Table&#x000a0;<xref ref-type="" rid="MOESM4">4</xref>) and was supported by the case-only analysis (ESM Table&#x000a0;<xref ref-type="" rid="MOESM5">5</xref>; 3&#x000a0;<italic>df</italic> test; <italic>p&#x02009;</italic>=&#x02009;0.57). Again, there was no association between the two loci among controls (3&#x000a0;<italic>df</italic> test; <italic>p&#x02009;</italic>=&#x02009;0.21). <table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Interaction between <italic>HLA-INS</italic> (<italic>-23HphI</italic>), <italic>HLA-PTPN22</italic> (<italic>Arg620Trp</italic>) and <italic>HLA-CTLA4</italic> (<italic>JO27_1</italic>) in the case&#x02013;control data set using logistic regression</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">HLA category<sup>a</sup></th><th rowspan="2">Non-HLA genotypes</th><th>Cases</th><th>Controls</th><th rowspan="2">OR</th><th rowspan="2">95% CI</th><th rowspan="2">Test for interaction (<italic>p</italic> value)</th></tr><tr><th><italic>n</italic> (%)</th><th><italic>n</italic> (<italic>%</italic>)</th></tr></thead><tbody><tr><td/><td><italic>INS</italic><sup>b</sup></td><td/><td/><td/><td/><td>0.67</td></tr><tr><td>High risk</td><td>I-I</td><td>218 (25.2)</td><td>20 (2.8)</td><td>1.56</td><td>0.76&#x02013;3.21</td><td/></tr><tr><td/><td>III+</td><td>98 (28.6)</td><td>14 (2.5)</td><td>1</td><td/><td/></tr><tr><td>Intermediate risk</td><td>I-I</td><td>412 (47.6)</td><td>122 (17.1)</td><td>2.10</td><td>1.52&#x02013;2.89</td><td/></tr><tr><td/><td>III+</td><td>160 (46.8)</td><td>99 (17.4)</td><td>1</td><td/><td/></tr><tr><td>Neutral risk</td><td>I-I</td><td>221 (25.5)</td><td>346 (48.5)</td><td>2.34</td><td>1.74&#x02013;3.15</td><td/></tr><tr><td/><td>III+</td><td>81 (23.7)</td><td>299 (52.6)</td><td>1</td><td/><td/></tr><tr><td>Low risk</td><td>I-I</td><td>14 (1.6)</td><td>225 (31.6)</td><td>3.26</td><td>0.92&#x02013;11.54</td><td/></tr><tr><td/><td>III+</td><td>3 (0.9)</td><td>156 (27.5)</td><td>1</td><td/><td/></tr><tr><td>Total</td><td/><td>1207</td><td>1281</td><td/><td/><td/></tr><tr><td/><td><italic>PTPN22</italic></td><td/><td/><td/><td/><td>0.024</td></tr><tr><td>High risk</td><td>TT&#x02009;+&#x02009;TC</td><td>89 (23.2)</td><td>8 (3.1)</td><td>1.26</td><td>0.55&#x02013;2.88</td><td/></tr><tr><td/><td>CC</td><td>237 (27.8)</td><td>27 (2.6)</td><td>1</td><td/><td/></tr><tr><td>Intermediate risk</td><td>TT&#x02009;+&#x02009;TC</td><td>177 (46.1)</td><td>55 (21.2)</td><td>1.31</td><td>0.91&#x02013;1.86</td><td/></tr><tr><td/><td>CC</td><td>406 (47.7)</td><td>164 (15.6)</td><td>1</td><td/><td/></tr><tr><td>Neutral risk</td><td>TT&#x02009;+&#x02009;TC</td><td>111 (28.9)</td><td>121 (46.7)</td><td>2.44</td><td>1.80&#x02013;3.31</td><td/></tr><tr><td/><td>CC</td><td>199 (23.4)</td><td>536 (51.0)</td><td>1</td><td/><td/></tr><tr><td>Low risk</td><td>TT&#x02009;+&#x02009;TC</td><td>7 (1.8)</td><td>75 (29.0)</td><td>3.27</td><td>1.18&#x02013;9.06</td><td/></tr><tr><td/><td>CC</td><td>9 (1.1)</td><td>323 (30.8)</td><td>1</td><td/><td/></tr><tr><td>Total</td><td/><td>1235</td><td>1309</td><td/><td/><td/></tr><tr><td/><td><italic>CTLA4</italic></td><td/><td/><td/><td/><td>0.53</td></tr><tr><td>High risk</td><td>TT</td><td>122 (24.9)</td><td>14 (3.6)</td><td>0.90</td><td>0.45&#x02013;1.84</td><td/></tr><tr><td/><td>TC-CC</td><td>210 (27.9)</td><td>22 (2.5)</td><td>1</td><td/><td/></tr><tr><td>Intermediate risk</td><td>TT</td><td>241 (49.2)</td><td>65 (16.5)</td><td>1.59</td><td>1.14&#x02013;2.23</td><td/></tr><tr><td/><td>TC-CC</td><td>346 (46.0)</td><td>148 (16.7)</td><td>1</td><td/><td/></tr><tr><td>Neutral risk</td><td>TT</td><td>121 (24.7)</td><td>212 (53.8)</td><td>1.34</td><td>1.01&#x02013;1.77</td><td/></tr><tr><td/><td>TC-CC</td><td>187 (24.9)</td><td>439 (49.7)</td><td>1</td><td/><td/></tr><tr><td>Low risk</td><td>TT</td><td>6 (1.2)</td><td>103 (26.1)</td><td>1.80</td><td>0.63&#x02013;5.18</td><td/></tr><tr><td/><td>TC-CC</td><td>9 (1.2)</td><td>275 (31.1)</td><td>1</td><td/><td/></tr><tr><td>Total</td><td/><td>1242</td><td>1278</td><td/><td/><td/></tr></tbody></table><table-wrap-foot><p><italic>n</italic>, Number of cases/controls</p><p><sup>a</sup>HLA risk categories: high risk, <italic>DQA1*03-DQB1*0302/DQA1*05-DQB1*0201</italic> (<italic>DQ8/DQ2</italic>), where <italic>DRB1&#x02260;0404</italic>; low risk, at least one <italic>DQB1*0602</italic> allele independent of genotype on the other allele; intermediate risk, <italic>DRB1*0404-DQ8/DR3-DQ2</italic>, <italic>DR3-DQ2/DR3-DQ2</italic>, <italic>DR4-DQ8/DR4-DQ8</italic> (excluding homozygous <italic>DRB1 0404</italic>), <italic>DRB1*0401</italic> or <italic>040x-DQ8/X</italic> (X&#x02260;<italic>DQB1*0602</italic> or <italic>DR3</italic>). The remaining haplotypes were grouped in the neutral risk category (see Methods)</p><p><sup>b</sup>Represents genotypes III/III and I/III</p></table-wrap-foot></table-wrap></p><p><bold>Joint effects of non-HLA loci</bold> There was also no indication of deviation from multiplicative two-locus joint effects of <italic>PTPN22-INS</italic>, <italic>INS</italic>-<italic>CTLA4</italic> or <italic>PTPN22-CTLA4</italic> in the case-control data (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) or in the case-only analysis (ESM Table&#x000a0;<xref ref-type="" rid="MOESM5">5</xref>) (all <italic>p&#x02009;</italic>&#x0003e;&#x02009;0.39). For the trios, the test for interaction between <italic>PTPN22</italic> and <italic>CTLA4</italic> showed <italic>p&#x02009;</italic>=&#x02009;0.046 (ESM Table&#x000a0;<xref ref-type="" rid="MOESM6">6</xref>). Taken together with the analysis of the case-control and the case-only data, this weighs against any deviation from a multiplicative two-locus joint effect also of <italic>CTLA4</italic> and <italic>PTPN22</italic>. <table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Interaction between <italic>INS-PTPN22</italic>, <italic>INS-CTLA4</italic> and <italic>PTPN22-CTLA4</italic> in the case-control data set using logistic regression</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2">Non-HLA genotypes</th><th>Cases</th><th>Controls</th><th rowspan="2">OR</th><th rowspan="2">95% CI</th><th rowspan="2">Test for interaction<sup>a</sup> (<italic>p</italic> value)</th></tr><tr><th><italic>n</italic> (%)</th><th><italic>n</italic> (%)</th></tr></thead><tbody><tr><td><italic>INS</italic></td><td>PTPN</td><td>&#x000a0;</td><td>&#x000a0;</td><td char="." align="char">&#x000a0;</td><td char="." align="char">&#x000a0;</td><td rowspan="6">0.67</td></tr><tr><td>I-I</td><td>TT+TC</td><td>274 (72.9)</td><td>156 (58.4)</td><td char="." align="char">1.74</td><td char="." align="char">1.38&#x02013;2.18</td></tr><tr><td>I-I</td><td>CC</td><td>594 (71.6)</td><td>587 (54.8)</td><td char="." align="char">1</td><td char="." align="char">&#x000a0;</td></tr><tr><td>III+</td><td>TT+TC</td><td>102 (27.1)</td><td>111 (41.6)</td><td char="." align="char">1.89</td><td char="." align="char">1.38&#x02013;2.58</td></tr><tr><td>III+</td><td>CC</td><td>236 (28.4)</td><td>485 (45.2)</td><td char="." align="char">1</td><td char="." align="char">&#x000a0;</td></tr><tr><td>Total (<italic>n</italic>)</td><td>&#x000a0;</td><td>1,206</td><td>1,339</td><td char="." align="char">&#x000a0;</td><td char="." align="char">&#x000a0;</td></tr><tr><td><italic>INS</italic></td><td>CTLA4</td><td>&#x000a0;</td><td>&#x000a0;</td><td char="." align="char">&#x000a0;</td><td char="." align="char">&#x000a0;</td><td rowspan="6">0.42</td></tr><tr><td>I-I</td><td>TT</td><td>354 (73.1)</td><td>222 (53.9)</td><td char="." align="char">1.51</td><td char="." align="char">1.23&#x02013;1.86</td></tr><tr><td>I-I</td><td>TC-CC</td><td>520 (71.0)</td><td>492 (54.8)</td><td char="." align="char">1</td><td char="." align="char">&#x000a0;</td></tr><tr><td>III+</td><td>TT</td><td>130 (26.9)</td><td>190 (46.1)</td><td char="." align="char">1.31</td><td char="." align="char">0.99&#x02013;1.73</td></tr><tr><td>III+</td><td>TC-CC</td><td>212 (29.0)</td><td>405 (45.2)</td><td char="." align="char">1</td><td char="." align="char">&#x000a0;</td></tr><tr><td>Total (<italic>n</italic>)</td><td>&#x000a0;</td><td>1,216</td><td>1,309</td><td char="." align="char">&#x000a0;</td><td char="." align="char">&#x000a0;</td></tr><tr><td><italic>PTPN</italic></td><td>CTLA4</td><td>&#x000a0;</td><td>&#x000a0;</td><td char="." align="char">&#x000a0;</td><td char="." align="char">&#x000a0;</td><td rowspan="6">0.78</td></tr><tr><td>TT+TC</td><td>TT</td><td>143 (29.7)</td><td>75 (17.7)</td><td char="." align="char">1.46</td><td char="." align="char">1.04&#x02013;2.05</td></tr><tr><td>TT+TC</td><td>TC-CC</td><td>239 (31.7)</td><td>183 (20.1)</td><td char="." align="char">1</td><td char="." align="char">&#x000a0;</td></tr><tr><td>CC</td><td>TT</td><td>339 (70.3)</td><td>348 (82.3)</td><td char="." align="char">1.4</td><td char="." align="char">1.15&#x02013;1.67</td></tr><tr><td>CC</td><td>TC-CC</td><td>514 (68.3)</td><td>729 (79.9)</td><td char="." align="char">1</td><td char="." align="char">&#x000a0;</td></tr><tr><td>Total (<italic>n</italic>)</td><td>&#x000a0;</td><td>1,235</td><td>1,335</td><td char="." align="char">&#x000a0;</td><td char="." align="char">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p>The low-risk genotypes were used as reference (CC, TC-CC, TC-CC)</p><p><sup>a</sup>Likelihood ratio tests of whether the OR conferred by one locus is significantly different over strata defined by genotypes in the other locus</p><p><italic>n</italic>, Number of cases/controls</p></table-wrap-foot></table-wrap></p><p><bold>Joint effects of more than two susceptibility loci</bold> We also tested models with all three-way and four-way interactions involving the four susceptibility loci using logistic regression (categorising all loci in two groups: increased risk genotypes or not), but none of the multi-way interactions were statistically significant (all <italic>p&#x02009;</italic>&#x0003e;&#x02009;0.29). The simultaneous distribution of risk genotypes at all four loci among cases and controls is shown in ESM Table&#x000a0;<xref ref-type="" rid="MOESM7">7</xref>. The results show that the more risk loci an individual carries, the higher the relative risk, but the presence or absence of HLA risk loci influences the relative risk much more than the other loci, as expected. For instance, carrying risk genotypes at all three non-HLA loci but not at HLA is associated with a much lower risk than HLA risk genotypes together with low-risk genotypes at all three other loci. The relative risk (OR) conferred by simultaneously carrying high- or moderate-risk HLA and risk genotypes at all the three other loci compared with non-risk-associated genotypes at all four loci was 61. The expected relative risk under a strict multiplicative model involving all four loci was 123 (multiplying all four single-locus effects by each other). The relatively small number of individuals simultaneously carrying all risk genotypes indicates that the observed negative deviation from a four-way multiplicative model was not statistically significant, in accordance with the formal test cited above.</p><p><bold>ROC curve</bold> Another way to assess the predictive utility of combinations of genetic risk markers is the ROC curve [<xref ref-type="bibr" rid="CR40">40</xref>]. This utilises the genotypes of all included individuals and assesses the combination of sensitivity and specificity of different combinations of genotypes. ROC curves for HLA alone, pairwise combinations of HLA and non-HLA loci, and multiple genotypes (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) showed an area under the curve of 0.82 for HLA alone, which was only marginally increased by adding non-HLA loci. <fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>ROC curve for HLA genotypes in four categories and for combinations of genotypes defined by HLA and non-HLA susceptibility loci. The area under the curve (95% confidence interval) was 0.820 (0.803&#x02013;0.836) for HLA (dark blue line), 0.828 (0.811&#x02013;0.844) for HLA+<italic>CTLA4</italic> (purple line), 0.835 (0.819&#x02013;0.851) for HLA+<italic>PTPN22</italic> (grey line), 0.840 (0.824&#x02013;0.855) for HLA+<italic>INS</italic> (green line), 0.848 (0.833&#x02013;0.863) for HLA+<italic>INS</italic>+<italic>PTPN22</italic> (yellow line) and 0.852 (0.837&#x02013;0.867) for HLA+<italic>INS</italic>+<italic>PTPN22</italic>+<italic>CTLA4</italic> (red line). Turquoise dashed line, reference line</p></caption><graphic position="anchor" xlink:href="125_2008_932_Fig1_HTML" id="MO1"/></fig></p><p><bold>Age of disease onset and sex</bold> We found no significant deviation from a multiplicative model concerning age&#x02013;locus and sex&#x02013;locus interaction for any of the genes. This was confirmed in the trio families and case-only analysis (ESM Tables&#x000a0;<xref ref-type="" rid="MOESM8">8</xref> and <xref ref-type="" rid="MOESM9">9</xref>).</p></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><p>The present study is a comprehensive evaluation of joint effects of the four most well established type 1 diabetes susceptibility genes in both a large case-control series and family material. The relative risk conferred by <italic>PTPN22</italic> was stronger in the lower-risk HLA categories than in the high-risk HLA category, while all other two-locus combinations (<italic>HLA-INS</italic>, <italic>HLA-CTLA4</italic>, <italic>INS-CTLA4</italic>, <italic>INS-PTPN22</italic> and <italic>PTPN22-CTLA4</italic>) were consistent with multiplicative models. Although model-free methods have been developed for gene&#x02013;gene interaction studies, such as multifactor dimensionality reduction (see [<xref ref-type="bibr" rid="CR1">1</xref>] and references therein), these methods are designed for the detection of novel susceptibility loci, which was not the goal of our investigation.</p><p>Two of the three previous studies of the joint effect of <italic>PTPN22</italic> and HLA were in accordance with our results [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>] while the other study found no deviation from a multiplicative model [<xref ref-type="bibr" rid="CR22">22</xref>]. It should be noted that the interaction between <italic>PTPN22</italic> and HLA found in the case-control material and case-only analysis was not replicated in our trio data. One of the reasons for this could be lower statistical power in the trio data. Using the Quanto program ([<xref ref-type="bibr" rid="CR41">41</xref>]; <ext-link ext-link-type="uri" xlink:href="http://hydra.usc.edu/gxe">http://hydra.usc.edu/gxe</ext-link>), we found that we had more than 80% power to detect significant two-way gene&#x02013;gene interaction if the true interaction parameter was 0.5. For the trio design we would need as many trios as we had cases in the case-control study to obtain a similar power. Our number of trios was only about a third of the number of cases in the case-control study, with consequently lower power. The case-only design is known to be the most efficient to detect interaction under certain assumptions. For instance, we had &#x0003e;99% power to detect interaction if the true interaction parameter was 0.5.</p><p>The few studies concerning two-locus interaction effects between HLA and <italic>CTLA4</italic> and among non-HLA genes [<xref ref-type="bibr" rid="CR22">22</xref>] have generally indicated multiplicative effects, which is in accordance with our results. Some previous studies have found that the relative risk conferred by <italic>INS</italic> was similar in subgroups defined by HLA susceptibility genes [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>], while three studies have indicated that the effect was stronger in the low risk-HLA categories [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>], a finding that was only partially supported by our data. On the other hand, one relatively small study has found that the effect of <italic>INS</italic> was confined to the high-risk <italic>HLA-DR4</italic> group [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>The reason for diverging results of the joint effect of established type 1 diabetes susceptibility genes in the literature could be that the studies have been performed with varying sample sizes and with different study designs. Linkage studies [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], case-control association studies [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>] and family trio designs [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] have all been used in these studies. Smaller studies might be inadequate to reveal significant interactions. Different criteria for categorising the HLA risk groups could potentially influence the result of the joint effect of HLA and other type 1 diabetes susceptibility genes. However, our conclusions were not affected by alternative classification of HLA risk groups, such as into <italic>DR4-DQ8</italic> vs <italic>DR3-DQ2</italic> carriers (data not shown). Studies in different populations and ethnic groups have indicated some heterogeneity in HLA-associated risk of type 1 diabetes and it is also possible that gene&#x02013;gene interactions may vary across populations. However, despite the observed variations in population risk of type 1 diabetes and in HLA haplotype frequencies across populations, the relative predisposing effects of HLA haplotypes seem to be consistent across populations [<xref ref-type="bibr" rid="CR42">42</xref>]. In our study all the patients were diagnosed before 15 years of age. The fact that the relative risks associated with both risk genotypes and low-risk genotypes seem to diminish with age above 15&#x000a0;years [<xref ref-type="bibr" rid="CR43">43</xref>] raises the question whether gene&#x02013;gene interactions may also differ in different age-groups.</p><p>Although no preventive intervention is available for type 1 diabetes today, prediction of disease is an important part of strategies for prevention, both for recruitment of participants for research studies and for identification of target populations for future preventive interventions. Understanding the interacting effect of the established type 1 diabetes susceptibility genes will increase this possibility. In a multiplicative model the relative risk (RR) for a person holding a high-risk genotype at both loci compared with a person with low risk at both loci will be RR<sub>locus1</sub>&#x02009;&#x000d7;&#x02009;RR<sub>locus2.</sub> In terms of absolute risk differences, a doubling or tripling of risk due to <italic>INS</italic> or <italic>PTPN22</italic> would be greater for a person with a high-risk HLA genotype than it would for someone with a low-risk HLA genotype. The absolute risk for persons with a given genotype can be estimated by multiplying the average cumulative incidence in the population (0.42% cumulative risk up to age 15&#x000a0;years in Norway [<xref ref-type="bibr" rid="CR44">44</xref>]) by the ratio of genotype frequency in patients and genotype frequency in controls [<xref ref-type="bibr" rid="CR18">18</xref>], or using Bayes&#x02019; formula. For instance, for a person with a low-risk HLA genotype, a high- or low-risk <italic>INS</italic> genotype will define whether the estimated absolute risk is approximately 0.01% or 0.028% (absolute risk difference, 0.027%), whereas for those with the high-risk HLA genotype <italic>INS</italic> will define an estimated risk of approximately 3.0% or 4.7% (absolute risk difference 1.7%).</p><p>As discussed in the general setting by Janssens et al. [<xref ref-type="bibr" rid="CR40">40</xref>], increasing the number of susceptibility loci considered simultaneously generally increases the predictive value for disease. The downside is that the proportion of the population simultaneously carrying multiple risk alleles becomes minute even with a moderate number of susceptibility polymorphisms, and that even with relatively large data sets, as in our study, the absolute risk estimate becomes imprecise. The high-risk HLA genotype is carried by fewer than 3% of population controls, but confers a very high risk of disease. Several practical and scientific aspects of prediction should be considered when evaluating the utility of different prediction regimes. The ROC curve analysis confirms that, despite the higher absolute risk for those few with combinations of several risk markers, adding non-HLA genetic markers only marginally increases the utility of the prediction over that of HLA alone. While up to six susceptibility loci in addition to those studied here have recently been established in type 1 diabetes [<xref ref-type="bibr" rid="CR45">45</xref>], the magnitude of the effect for each additional locus is very much smaller than that of HLA and even smaller than that of <italic>INS</italic> and <italic>PTPN22</italic>, suggesting that they are likely to add only marginally to the prediction of disease in individuals. Furthermore, an informal assessment of the number needed to be genetically screened in order to obtain a cohort of high-risk individuals, which will give rise to a given number of cases of type 1 diabetes, and the costs connected to the genotyping also suggest limited cost-effectiveness in adding non-HLA genetic markers to the prediction regime (data not shown).</p><p>In conclusion, in this comprehensive study of interactions among established type 1 diabetes susceptibility genes, we found that the joint effect of HLA and <italic>PTPN22</italic> was significantly less than multiplicative in the case-control material, while a multiplicative model could not be rejected for <italic>HLA-INS</italic>, <italic>HLA-CTLA</italic>, <italic>PTPN-INS</italic>, <italic>INS-CTLA4</italic> and <italic>PTPN-CTLA4</italic>. Despite near-multiplicative effects for most loci, and the fact that groups with very high relative risk of type 1 diabetes can be identified by testing for multiple susceptibility genes, only a small proportion of the population (and cases with type 1 diabetes) simultaneously carry HLA and multiple non<italic>-</italic>HLA susceptibility genotypes.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><supplementary-material id="N0x1d01140N0x2d0bda0" content-type="local-data"><p>Below is the link to the electronic supplementary material. </p><media xlink:href="125_2008_932_MOESM1_ESM.pdf" id="MOESM1" mimetype="application" mime-subtype="pdf"><label>ESM Table&#x000a0;1</label><caption><p>(PDF 14.3 kb)</p></caption></media><media xlink:href="125_2008_932_MOESM2_ESM.pdf" id="MOESM2" mimetype="application" mime-subtype="pdf"><label>ESM Table&#x000a0;2</label><caption><p>(PDF 110 kb)</p></caption></media><media xlink:href="125_2008_932_MOESM3_ESM.pdf" id="MOESM3" mimetype="application" mime-subtype="pdf"><label>ESM Table&#x000a0;3</label><caption><p>(PDF 69.2 kb)</p></caption></media><media xlink:href="125_2008_932_MOESM4_ESM.pdf" id="MOESM4" mimetype="application" mime-subtype="pdf"><label>ESM Table&#x000a0;4</label><caption><p>(PDF 51.2 kb)</p></caption></media><media xlink:href="125_2008_932_MOESM5_ESM.pdf" id="MOESM5" mimetype="application" mime-subtype="pdf"><label>ESM Table&#x000a0;5</label><caption><p>(PDF 31.9 kb)</p></caption></media><media xlink:href="125_2008_932_MOESM6_ESM.pdf" id="MOESM6" mimetype="application" mime-subtype="pdf"><label>ESM Table&#x000a0;6</label><caption><p>(PDF 48.8 kb)</p></caption></media><media xlink:href="125_2008_932_MOESM7_ESM.pdf" id="MOESM7" mimetype="application" mime-subtype="pdf"><label>ESM Table&#x000a0;7</label><caption><p>(PDF 25.9 kb)</p></caption></media><media xlink:href="125_2008_932_MOESM8_ESM.pdf" id="MOESM8" mimetype="application" mime-subtype="pdf"><label>ESM Table&#x000a0;8</label><caption><p>(PDF 68.0 kb)</p></caption></media><media xlink:href="125_2008_932_MOESM9_ESM.pdf" id="MOESM9" mimetype="application" mime-subtype="pdf"><label>ESM Table&#x000a0;9</label><caption><p>(PDF 25.1 kb)</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgement</title><p>This work was supported by The National Programme for Research in Functional Genomics in Norway (FUGE), Research Council of Norway, University of Oslo and Eastern Norway Regional Health Authority. G. Joner and L. C. Stene were supported by grants from the Research Council of Norway (148359/330), Norwegian Diabetes Association, Aker Diabetes Research Foundation and Novo Nordisk Fonden. P. R. Nj&#x000f8;lstad was supported by funds from University of Bergen, and Western Norway Regional Health Authority, Haukeland University Hospital/Innovest, Research Council of Norway (FUGE Programme) and Novo Nordisk Fonden. We thank P. M. Thorsby, J. P. Berg and V. Enge at The Hormone Laboratory, Aker University Hospital, for help with <italic>INS</italic> genotyping.</p><p><bold>Duality of interest</bold> The authors declare that there is no duality of interest associated with this manuscript.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>JH</given-names></name></person-group><article-title>The ubiquitous nature of epistasis in determining susceptibility to common human diseases</article-title><source>Hum Hered</source><year>2003</year><volume>56</volume><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1159/000073735</pub-id></citation><citation citation-type="display-unstructured">Moore JH (2003) The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered 56:73&#x02013;82 <pub-id pub-id-type="pmid">14614241</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cordell</surname><given-names>HJ</given-names></name></person-group><article-title>Epistasis: what it means, what it doesn&#x02019;t mean, and statistical methods to detect it in humans</article-title><source>Hum Mol Genet</source><year>2002</year><volume>11</volume><fpage>2463</fpage><lpage>2468</lpage><pub-id pub-id-type="doi">10.1093/hmg/11.20.2463</pub-id></citation><citation citation-type="display-unstructured">Cordell HJ (2002) Epistasis: what it means, what it doesn&#x02019;t mean, and statistical methods to detect it in humans. Hum Mol Genet 11:2463&#x02013;2468 <pub-id pub-id-type="pmid">12351582</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Reich</surname><given-names>J</given-names></name></person-group><article-title>A complete enumeration and classification of two-locus disease models</article-title><source>Hum Hered</source><year>2000</year><volume>50</volume><fpage>334</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1159/000022939</pub-id></citation><citation citation-type="display-unstructured">Li W, Reich J (2000) A complete enumeration and classification of two-locus disease models. Hum Hered 50:334&#x02013;349 <pub-id pub-id-type="pmid">10899752</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Lohmueller</surname><given-names>K</given-names></name><name><surname>Byrne</surname><given-names>E</given-names></name><name><surname>Hirschhorn</surname><given-names>K</given-names></name></person-group><article-title>A comprehensive review of genetic association studies</article-title><source>Genet Med</source><year>2002</year><volume>4</volume><fpage>45</fpage><lpage>61</lpage></citation><citation citation-type="display-unstructured">Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K (2002) A comprehensive review of genetic association studies. Genet Med 4:45&#x02013;61 <pub-id pub-id-type="pmid">11882781</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Undlien</surname><given-names>DE</given-names></name><name><surname>Lie</surname><given-names>BA</given-names></name><name><surname>Thorsby</surname><given-names>E</given-names></name></person-group><article-title>HLA complex genes in type 1 diabetes and other autoimmune diseases. Which genes are involved?</article-title><source>Trends Genet</source><year>2001</year><volume>17</volume><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/S0168-9525(00)02180-6</pub-id></citation><citation citation-type="display-unstructured">Undlien DE, Lie BA, Thorsby E (2001) HLA complex genes in type 1 diabetes and other autoimmune diseases. Which genes are involved? Trends Genet 17:93&#x02013;100 <pub-id pub-id-type="pmid">11173119</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>H</given-names></name><name><surname>Howson</surname><given-names>JMM</given-names></name><name><surname>Esposito</surname><given-names>L</given-names></name><etal/></person-group><article-title>Association of the T cell regulatory gene CTLA4 with susceptibility to autoimmune disease</article-title><source>Nature</source><year>2003</year><volume>423</volume><fpage>506</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1038/nature01621</pub-id></citation><citation citation-type="display-unstructured">Ueda H, Howson JMM, Esposito L et al (2003) Association of the T cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506&#x02013;511 <pub-id pub-id-type="pmid">12724780</pub-id></citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pugliese</surname><given-names>A</given-names></name><name><surname>Miceli</surname><given-names>D</given-names></name></person-group><article-title>The insulin gene in diabetes</article-title><source>Diabetes Metab Res Rev</source><year>2002</year><volume>18</volume><fpage>13</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1002/dmrr.261</pub-id></citation><citation citation-type="display-unstructured">Pugliese A, Miceli D (2002) The insulin gene in diabetes. Diabetes Metab Res Rev 18:13&#x02013;25 <pub-id pub-id-type="pmid">11921414</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bottini</surname><given-names>N</given-names></name><name><surname>Musumeci</surname><given-names>L</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><etal/></person-group><article-title>A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes</article-title><source>Nat Genet</source><year>2004</year><volume>36</volume><fpage>337</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/ng1323</pub-id></citation><citation citation-type="display-unstructured">Bottini N, Musumeci L, Alonso A et al (2004) A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 36:337&#x02013;338 <pub-id pub-id-type="pmid">15004560</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>WD</given-names></name></person-group><article-title>Effect modification and the limits of biological inference from epidemiologic data</article-title><source>J Clin Epidemiol</source><year>1991</year><volume>44</volume><fpage>221</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/0895-4356(91)90033-6</pub-id></citation><citation citation-type="display-unstructured">Thompson WD (1991) Effect modification and the limits of biological inference from epidemiologic data. J Clin Epidemiol 44:221&#x02013;232 <pub-id pub-id-type="pmid">1999681</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Julier</surname><given-names>C</given-names></name><name><surname>Hyer</surname><given-names>RN</given-names></name><name><surname>Davies</surname><given-names>J</given-names></name><etal/></person-group><article-title>Insulin-IGF2 region on chromosome 11p encodes a gene implicated in HLA-DR4-dependent diabetes susceptibility</article-title><source>Nature</source><year>1991</year><volume>354</volume><fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1038/354155a0</pub-id></citation><citation citation-type="display-unstructured">Julier C, Hyer RN, Davies J et al (1991) Insulin-IGF2 region on chromosome 11p encodes a gene implicated in HLA-DR4-dependent diabetes susceptibility. Nature 354:155&#x02013;159 <pub-id pub-id-type="pmid">1944595</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bain</surname><given-names>SC</given-names></name><name><surname>Prins</surname><given-names>JB</given-names></name><name><surname>Hearne</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Insulin gene region-encoded susceptibility to type 1 diabetes is not restricted to HLA-DR4-positive individuals</article-title><source>Nat Genet</source><year>1992</year><volume>2</volume><fpage>212</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1038/ng1192-212</pub-id></citation><citation citation-type="display-unstructured">Bain SC, Prins JB, Hearne CM et al (1992) Insulin gene region-encoded susceptibility to type 1 diabetes is not restricted to HLA-DR4-positive individuals. Nat Genet 2:212&#x02013;215 <pub-id pub-id-type="pmid">1345171</pub-id></citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Auwera</surname><given-names>BJ</given-names></name><name><surname>Heimberg</surname><given-names>H</given-names></name><name><surname>Schrevens</surname><given-names>AF</given-names></name><name><surname>Van</surname><given-names>WC</given-names></name><name><surname>Flament</surname><given-names>J</given-names></name><name><surname>Schuit</surname><given-names>FC</given-names></name></person-group><article-title>5&#x02032; Insulin gene polymorphism confers risk to IDDM independently of HLA class II susceptibility</article-title><source>Diabetes</source><year>1993</year><volume>42</volume><fpage>851</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.2337/diabetes.42.6.851</pub-id></citation><citation citation-type="display-unstructured">van der Auwera BJ, Heimberg H, Schrevens AF, Van WC, Flament J, Schuit FC (1993) 5&#x02032; Insulin gene polymorphism confers risk to IDDM independently of HLA class II susceptibility. Diabetes 42:851&#x02013;854 <pub-id pub-id-type="pmid">8495808</pub-id></citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>She</surname><given-names>JX</given-names></name><name><surname>Bui</surname><given-names>MM</given-names></name><name><surname>Tian</surname><given-names>XH</given-names></name><etal/></person-group><article-title>Additive susceptibility to insulin-dependent diabetes conferred by HLA-DQB1 and insulin genes</article-title><source>Autoimmunity</source><year>1994</year><volume>18</volume><fpage>195</fpage><lpage>203</lpage></citation><citation citation-type="display-unstructured">She JX, Bui MM, Tian XH et al (1994) Additive susceptibility to insulin-dependent diabetes conferred by HLA-DQB1 and insulin genes. Autoimmunity 18:195&#x02013;203 <pub-id pub-id-type="pmid">7858104</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dizier</surname><given-names>MH</given-names></name><name><surname>Babron</surname><given-names>MC</given-names></name><name><surname>Clerget-Darpoux</surname><given-names>F</given-names></name></person-group><article-title>Interactive effect of two candidate genes in a disease: extension of the marker-association-segregation chi square method</article-title><source>Am J Hum Genet</source><year>1994</year><volume>55</volume><fpage>1042</fpage><lpage>1049</lpage></citation><citation citation-type="display-unstructured">Dizier MH, Babron MC, Clerget-Darpoux F (1994) Interactive effect of two candidate genes in a disease: extension of the marker-association-segregation chi square method. Am J Hum Genet 55:1042&#x02013;1049 <pub-id pub-id-type="pmid">7977341</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cordell</surname><given-names>HJ</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name><name><surname>Bennett</surname><given-names>ST</given-names></name><name><surname>Kawaguchi</surname><given-names>Y</given-names></name><name><surname>Farrall</surname><given-names>M</given-names></name></person-group><article-title>Two-locus maximum lod score analysis of a multifactorial trait: joint consideration of IDDM2 and IDDM4 with IDDM1 in type 1 diabetes</article-title><source>Am J Hum Genet</source><year>1995</year><volume>57</volume><fpage>920</fpage><lpage>934</lpage></citation><citation citation-type="display-unstructured">Cordell HJ, Todd JA, Bennett ST, Kawaguchi Y, Farrall M (1995) Two-locus maximum lod score analysis of a multifactorial trait: joint consideration of IDDM2 and IDDM4 with IDDM1 in type 1 diabetes. Am J Hum Genet 57:920&#x02013;934 <pub-id pub-id-type="pmid">7573054</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Metcalfe</surname><given-names>KA</given-names></name><name><surname>Hitman</surname><given-names>GA</given-names></name><name><surname>Fennessy</surname><given-names>MJ</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Tuomilehto-Wolf</surname><given-names>E</given-names></name></person-group><article-title>In Finland insulin gene region encoded susceptibility to IDDM exerts maximum effect when there is low HLA-DR associated risk</article-title><source>Diabetologia</source><year>1995</year><volume>38</volume><fpage>1223</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1007/BF00422373</pub-id></citation><citation citation-type="display-unstructured">Metcalfe KA, Hitman GA, Fennessy MJ, McCarthy MI, Tuomilehto J, Tuomilehto-Wolf E (1995) In Finland insulin gene region encoded susceptibility to IDDM exerts maximum effect when there is low HLA-DR associated risk. Diabetologia 38:1223&#x02013;1229 <pub-id pub-id-type="pmid">8690176</pub-id></citation></ref><ref id="CR17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laine</surname><given-names>AP</given-names></name><name><surname>Hermann</surname><given-names>R</given-names></name><name><surname>Knip</surname><given-names>M</given-names></name><name><surname>Simell</surname><given-names>O</given-names></name><name><surname>Akerblom</surname><given-names>HK</given-names></name><name><surname>Ilonen</surname><given-names>J</given-names></name></person-group><article-title>The human leukocyte antigen genotype has a modest effect on the insulin gene polymorphism-associated susceptibility to type 1 diabetes in the Finnish population</article-title><source>Tissue Antigens</source><year>2004</year><volume>63</volume><fpage>72</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0039.2004.00153.x</pub-id></citation><citation citation-type="display-unstructured">Laine AP, Hermann R, Knip M, Simell O, Akerblom HK, Ilonen J (2004) The human leukocyte antigen genotype has a modest effect on the insulin gene polymorphism-associated susceptibility to type 1 diabetes in the Finnish population. Tissue Antigens 63:72&#x02013;74 <pub-id pub-id-type="pmid">14651526</pub-id></citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Motzo</surname><given-names>C</given-names></name><name><surname>Contu</surname><given-names>D</given-names></name><name><surname>Cordell</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Heterogeneity in the magnitude of the insulin gene effect on HLA risk in type 1 diabetes</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><fpage>3286</fpage><lpage>3291</lpage><pub-id pub-id-type="doi">10.2337/diabetes.53.12.3286</pub-id></citation><citation citation-type="display-unstructured">Motzo C, Contu D, Cordell HJ et al (2004) Heterogeneity in the magnitude of the insulin gene effect on HLA risk in type 1 diabetes. Diabetes 53:3286&#x02013;3291 <pub-id pub-id-type="pmid">15561961</pub-id></citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>PC</given-names></name></person-group><article-title>The language of gene interaction</article-title><source>Genetics</source><year>1998</year><volume>149</volume><fpage>1167</fpage><lpage>1171</lpage></citation><citation citation-type="display-unstructured">Phillips PC (1998) The language of gene interaction. Genetics 149:1167&#x02013;1171 <pub-id pub-id-type="pmid">9649511</pub-id></citation></ref><ref id="CR20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Risch</surname><given-names>N</given-names></name></person-group><article-title>Linkage strategies for genetically complex traits</article-title><source>I. Multilocus models. Am J Hum Genet</source><year>1990</year><volume>46</volume><fpage>222</fpage><lpage>228</lpage></citation><citation citation-type="display-unstructured">Risch N (1990) Linkage strategies for genetically complex traits. I. Multilocus models. Am J Hum Genet 46:222&#x02013;228 </citation></ref><ref id="CR21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wade</surname><given-names>MJ</given-names></name><name><surname>Winther</surname><given-names>RG</given-names></name><name><surname>Agrawal</surname><given-names>AF</given-names></name><name><surname>Goodnight</surname><given-names>CJ</given-names></name></person-group><article-title>Alternative definitions of epistasis: dependence and interaction</article-title><source>Trends Ecol Evol</source><year>2001</year><volume>16</volume><fpage>498</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/S0169-5347(01)02213-3</pub-id></citation><citation citation-type="display-unstructured">Wade MJ, Winther RG, Agrawal AF, Goodnight CJ (2001) Alternative definitions of epistasis: dependence and interaction. Trends Ecol Evol 16:498&#x02013;504 </citation></ref><ref id="CR22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>D</given-names></name><name><surname>Cooper</surname><given-names>JD</given-names></name><name><surname>Collins</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><fpage>3020</fpage><lpage>3023</lpage><pub-id pub-id-type="doi">10.2337/diabetes.53.11.3020</pub-id></citation><citation citation-type="display-unstructured">Smyth D, Cooper JD, Collins JE et al (2004) Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 53:3020&#x02013;3023 <pub-id pub-id-type="pmid">15504986</pub-id></citation></ref><ref id="CR23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Auwera</surname><given-names>B</given-names></name><name><surname>Vandewalle</surname><given-names>CL</given-names></name><name><surname>Schuit</surname><given-names>FC</given-names></name><etal/></person-group><article-title>CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers</article-title><source>Clin Exp Immunol</source><year>1997</year><volume>110</volume><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.1997.t01-1-512-ce1410.x</pub-id></citation><citation citation-type="display-unstructured">van der Auwera B, Vandewalle CL, Schuit FC et al (1997) CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. Clin Exp Immunol 110:98&#x02013;103 <pub-id pub-id-type="pmid">9353155</pub-id></citation></ref><ref id="CR24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Felner</surname><given-names>EI</given-names></name><name><surname>Klitz</surname><given-names>W</given-names></name><name><surname>Ham</surname><given-names>M</given-names></name><etal/></person-group><article-title>Genetic interaction among three genomic regions creates distinct contributions to early- and late-onset type 1 diabetes mellitus</article-title><source>Pediatr Diabet</source><year>2005</year><volume>6</volume><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1111/j.1399-543X.2005.00132.x</pub-id></citation><citation citation-type="display-unstructured">Felner EI, Klitz W, Ham M et al (2005) Genetic interaction among three genomic regions creates distinct contributions to early- and late-onset type 1 diabetes mellitus. Pediatr Diabet 6:213&#x02013;220 </citation></ref><ref id="CR25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hermann</surname><given-names>R</given-names></name><name><surname>Lipponen</surname><given-names>K</given-names></name><name><surname>Kiviniemi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><fpage>1198</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1007/s00125-006-0225-4</pub-id></citation><citation citation-type="display-unstructured">Hermann R, Lipponen K, Kiviniemi M et al (2006) Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes. Diabetologia 49:1198&#x02013;1208 <pub-id pub-id-type="pmid">16614815</pub-id></citation></ref><ref id="CR26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kahles</surname><given-names>H</given-names></name><name><surname>Ramos-Lopez</surname><given-names>E</given-names></name><name><surname>Lange</surname><given-names>B</given-names></name><name><surname>Zwermann</surname><given-names>O</given-names></name><name><surname>Reincke</surname><given-names>M</given-names></name><name><surname>Badenhoop</surname><given-names>K</given-names></name></person-group><article-title>Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto&#x02019;s thyroiditis or Addison&#x02019;s disease in the German population</article-title><source>Eur J Endocrinol</source><year>2005</year><volume>153</volume><fpage>895</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1530/eje.1.02035</pub-id></citation><citation citation-type="display-unstructured">Kahles H, Ramos-Lopez E, Lange B, Zwermann O, Reincke M, Badenhoop K (2005) Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto&#x02019;s thyroiditis or Addison&#x02019;s disease in the German population. Eur J Endocrinol 153:895&#x02013;899 <pub-id pub-id-type="pmid">16322396</pub-id></citation></ref><ref id="CR27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steck</surname><given-names>AK</given-names></name><name><surname>Liu</surname><given-names>SY</given-names></name><name><surname>McFann</surname><given-names>K</given-names></name><etal/></person-group><article-title>Association of the PTPN22/LYP gene with type 1 diabetes</article-title><source>Pediatr Diabetes</source><year>2006</year><volume>7</volume><fpage>274</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1111/j.1399-5448.2006.00202.x</pub-id></citation><citation citation-type="display-unstructured">Steck AK, Liu SY, McFann K et al (2006) Association of the PTPN22/LYP gene with type 1 diabetes. Pediatr Diabetes 7:274&#x02013;278 <pub-id pub-id-type="pmid">17054449</pub-id></citation></ref><ref id="CR28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stene</surname><given-names>LC</given-names></name><name><surname>Joner</surname><given-names>G</given-names></name><collab>the Norwegian Childhood Diabetes Study Group</collab></person-group><article-title>Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study</article-title><source>Am J Clin Nutr</source><year>2003</year><volume>78</volume><fpage>1128</fpage><lpage>1134</lpage></citation><citation citation-type="display-unstructured">Stene LC, Joner G, the Norwegian Childhood Diabetes Study Group (2003) Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr 78:1128&#x02013;1134 <pub-id pub-id-type="pmid">14668274</pub-id></citation></ref><ref id="CR29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stene</surname><given-names>LC</given-names></name><name><surname>Thorsby</surname><given-names>PM</given-names></name><name><surname>Berg</surname><given-names>JP</given-names></name><etal/></person-group><article-title>The relation between size at birth and risk of type 1 diabetes is not influenced by adjustment for the insulin gene (-23HphI) polymorphism or <italic>HLA-DQ</italic> genotype</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><fpage>2068</fpage><lpage>2073</lpage><pub-id pub-id-type="doi">10.1007/s00125-006-0292-6</pub-id></citation><citation citation-type="display-unstructured">Stene LC, Thorsby PM, Berg JP et al (2006) The relation between size at birth and risk of type 1 diabetes is not influenced by adjustment for the insulin gene (-23HphI) polymorphism or HLA-DQ genotype. Diabetologia 49:2068&#x02013;2073 <pub-id pub-id-type="pmid">16691379</pub-id></citation></ref><ref id="CR30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><collab>EURODIAB ACE Study G</collab></person-group><article-title>Variation and trends in incidence of childhood diabetes in Europe</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>873</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(99)07125-1</pub-id></citation><citation citation-type="display-unstructured">EURODIAB ACE Study G (2000) Variation and trends in incidence of childhood diabetes in Europe. Lancet 355:873&#x02013;876 <pub-id pub-id-type="pmid">10752702</pub-id></citation></ref><ref id="CR31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wits&#x000f8;</surname><given-names>E</given-names></name><name><surname>Stene</surname><given-names>LC</given-names></name><name><surname>Paltiel</surname><given-names>L</given-names></name><name><surname>Joner</surname><given-names>G</given-names></name><name><surname>R&#x000f8;nningen</surname><given-names>KS</given-names></name></person-group><article-title>DNA extraction and HLA genotyping using mailed mouth brushes from children</article-title><source>Pediatric Diabetes</source><year>2002</year><volume>3</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1034/j.1399-5448.2002.30205.x</pub-id></citation><citation citation-type="display-unstructured">Wits&#x000f8; E, Stene LC, Paltiel L, Joner G, R&#x000f8;nningen KS (2002) DNA extraction and HLA genotyping using mailed mouth brushes from children. Pediatric Diabetes 3:89&#x02013;94 <pub-id pub-id-type="pmid">15016162</pub-id></citation></ref><ref id="CR32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Helland</surname><given-names>A</given-names></name><name><surname>B&#x000f8;rresen</surname><given-names>AL</given-names></name><name><surname>Kristensen</surname><given-names>G</given-names></name><name><surname>R&#x000f8;nningen</surname><given-names>KS</given-names></name></person-group><article-title>DQA1 and DQB1 genes in patients with squamous cell carcinoma of the cervix: relationship to human papillomavirus infection and prognosis</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>1994</year><volume>3</volume><fpage>479</fpage><lpage>486</lpage></citation><citation citation-type="display-unstructured">Helland A, B&#x000f8;rresen AL, Kristensen G, R&#x000f8;nningen KS (1994) DQA1 and DQB1 genes in patients with squamous cell carcinoma of the cervix: relationship to human papillomavirus infection and prognosis. Cancer Epidemiol Biomarkers Prev 3:479&#x02013;486 <pub-id pub-id-type="pmid">8000298</pub-id></citation></ref><ref id="CR33"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cinek</surname><given-names>O</given-names></name><name><surname>Kolouskova</surname><given-names>S</given-names></name><name><surname>Snajderova</surname><given-names>M</given-names></name><etal/></person-group><article-title>HLA class II genetic association of type 1 diabetes mellitus in Czech children</article-title><source>Pediatric Diabetes</source><year>2001</year><volume>2</volume><fpage>98</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1034/j.1399-5448.2001.002003098.x</pub-id></citation><citation citation-type="display-unstructured">Cinek O, Kolouskova S, Snajderova M et al (2001) HLA class II genetic association of type 1 diabetes mellitus in Czech children. Pediatric Diabetes 2:98&#x02013;102 <pub-id pub-id-type="pmid">15016191</pub-id></citation></ref><ref id="CR34"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olerup</surname><given-names>O</given-names></name><name><surname>Aldener</surname><given-names>A</given-names></name><name><surname>Fogdell</surname><given-names>A</given-names></name></person-group><article-title>HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours</article-title><source>Tissue Antigens</source><year>1993</year><volume>41</volume><fpage>119</fpage><lpage>134</lpage></citation><citation citation-type="display-unstructured">Olerup O, Aldener A, Fogdell A (1993) HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens 41:119&#x02013;134 <pub-id pub-id-type="pmid">8316943</pub-id></citation></ref><ref id="CR35"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Undlien</surname><given-names>DE</given-names></name><name><surname>Friede</surname><given-names>T</given-names></name><name><surname>Rammensee</surname><given-names>HG</given-names></name><etal/></person-group><article-title>HLA-encoded genetic predisposition in IDDM: DR4 subtypes may be associated with different degrees of protection</article-title><source>Diabetes</source><year>1997</year><volume>46</volume><fpage>143</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.2337/diabetes.46.1.143</pub-id></citation><citation citation-type="display-unstructured">Undlien DE, Friede T, Rammensee HG et al (1997) HLA-encoded genetic predisposition in IDDM: DR4 subtypes may be associated with different degrees of protection. Diabetes 46:143&#x02013;149 <pub-id pub-id-type="pmid">8971095</pub-id></citation></ref><ref id="CR36"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piegorsch</surname><given-names>WW</given-names></name><name><surname>Weinberg</surname><given-names>CR</given-names></name><name><surname>Taylor</surname><given-names>JA</given-names></name></person-group><article-title>Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies</article-title><source>Stat Med</source><year>1994</year><volume>13</volume><fpage>153</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1002/sim.4780130206</pub-id></citation><citation citation-type="display-unstructured">Piegorsch WW, Weinberg CR, Taylor JA (1994) Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat Med 13:153&#x02013;162 <pub-id pub-id-type="pmid">8122051</pub-id></citation></ref><ref id="CR37"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ewens</surname><given-names>WJ</given-names></name><name><surname>Spielman</surname><given-names>RS</given-names></name></person-group><article-title>The transmission/disequilibrium test: history, subdivision and admixture</article-title><source>Am J Hum Genet</source><year>1995</year><volume>57</volume><fpage>455</fpage><lpage>464</lpage></citation><citation citation-type="display-unstructured">Ewens WJ, Spielman RS (1995) The transmission/disequilibrium test: history, subdivision and admixture. Am J Hum Genet 57:455&#x02013;464 <pub-id pub-id-type="pmid">7668272</pub-id></citation></ref><ref id="CR38"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dudbridge</surname><given-names>F</given-names></name></person-group><article-title>Pedigree disequilibrium tests for multilocus haplotypes</article-title><source>Genet Epidemiol</source><year>2003</year><volume>25</volume><fpage>115</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1002/gepi.10252</pub-id></citation><citation citation-type="display-unstructured">Dudbridge F (2003) Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25:115&#x02013;121 <pub-id pub-id-type="pmid">12916020</pub-id></citation></ref><ref id="CR39"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skrondal</surname><given-names>A</given-names></name></person-group><article-title>Interaction as departure from additivity in case-control studies: a cautionary note</article-title><source>Am J Epidemiol</source><year>2003</year><volume>158</volume><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1093/aje/kwg113</pub-id></citation><citation citation-type="display-unstructured">Skrondal A (2003) Interaction as departure from additivity in case-control studies: a cautionary note. Am J Epidemiol 158:251&#x02013;258 <pub-id pub-id-type="pmid">12882947</pub-id></citation></ref><ref id="CR40"><label>40.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Janssens</surname><given-names>AC</given-names></name><name><surname>Pardo</surname><given-names>MC</given-names></name><name><surname>Steyerberg</surname><given-names>EW</given-names></name><name><surname>Duijn</surname><given-names>CM</given-names></name></person-group><article-title>Revisiting the clinical validity of multiplex genetic testing in complex diseases</article-title><source>Am J Hum Genet</source><year>2004</year><volume>74</volume><fpage>585</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1086/382052</pub-id></citation><citation citation-type="display-unstructured">Janssens AC, Pardo MC, Steyerberg EW, van Duijn CM (2004) Revisiting the clinical validity of multiplex genetic testing in complex diseases. Am J Hum Genet 74:585&#x02013;588 <pub-id pub-id-type="pmid">14973786</pub-id></citation></ref><ref id="CR41"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gauderman</surname><given-names>WJ</given-names></name></person-group><article-title>Sample size requirements for association studies of gene-gene interaction</article-title><source>Am J Epidemiol</source><year>2002</year><volume>155</volume><fpage>478</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1093/aje/155.5.478</pub-id></citation><citation citation-type="display-unstructured">Gauderman WJ (2002) Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 155:478&#x02013;484 <pub-id pub-id-type="pmid">11867360</pub-id></citation></ref><ref id="CR42"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>G</given-names></name><name><surname>Valdes</surname><given-names>AM</given-names></name><name><surname>Noble</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis</article-title><source>Tissue Antigens</source><year>2007</year><volume>70</volume><fpage>110</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0039.2007.00867.x</pub-id></citation><citation citation-type="display-unstructured">Thomson G, Valdes AM, Noble JA et al (2007) Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis. Tissue Antigens 70:110&#x02013;127 <pub-id pub-id-type="pmid">17610416</pub-id></citation></ref><ref id="CR43"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabbah</surname><given-names>E</given-names></name><name><surname>Savola</surname><given-names>K</given-names></name><name><surname>Ebeling</surname><given-names>T</given-names></name><etal/></person-group><article-title>Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes</article-title><source>Diabetes Care</source><year>2000</year><volume>23</volume><fpage>1326</fpage><lpage>1332</lpage><pub-id pub-id-type="doi">10.2337/diacare.23.9.1326</pub-id></citation><citation citation-type="display-unstructured">Sabbah E, Savola K, Ebeling T et al (2000) Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 23:1326&#x02013;1332 <pub-id pub-id-type="pmid">10977027</pub-id></citation></ref><ref id="CR44"><label>44.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aamodt</surname><given-names>G</given-names></name><name><surname>Stene</surname><given-names>LC</given-names></name><name><surname>Nj&#x000f8;lstad</surname><given-names>PR</given-names></name><name><surname>S&#x000f8;vik</surname><given-names>O</given-names></name><name><surname>Joner</surname><given-names>G</given-names></name></person-group><article-title>Spatiotemporal trends and age-period-cohort modeling of the incidence of type 1 diabetes among children aged &#x0003c;15&#x000a0;years in Norway 1973&#x02013;1982 and 1989&#x02013;2003</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>884</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.2337/dc06-1568</pub-id></citation><citation citation-type="display-unstructured">Aamodt G, Stene LC, Nj&#x000f8;lstad PR, S&#x000f8;vik O, Joner G (2007) Spatiotemporal trends and age-period-cohort modeling of the incidence of type 1 diabetes among children aged &#x0003c;15&#x000a0;years in Norway 1973&#x02013;1982 and 1989&#x02013;2003. Diabetes Care 30:884&#x02013;889 <pub-id pub-id-type="pmid">17392550</pub-id></citation></ref><ref id="CR45"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Todd</surname><given-names>JA</given-names></name><name><surname>Walker</surname><given-names>NM</given-names></name><name><surname>Cooper</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>857</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1038/ng2068</pub-id></citation><citation citation-type="display-unstructured">Todd JA, Walker NM, Cooper JD et al (2007) Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39:857&#x02013;864 <pub-id pub-id-type="pmid">17554260</pub-id></citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>ROC</term><def><p>receiver operating characteristic</p></def></def-item><def-item><term>SNP</term><def><p>single nucleotide polymorphism</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1007/s00125-008-0932-0) contains supplementary material, which is available to authorised users.</p></fn></fn-group></back></article> 